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Background: Atherosclerosis is the main cause of morbidity and mortality in Western countries and carotid plaque
rupture is associated to acute events and responsible of 15-20% of all ischemic strokes. Several proteomics
approaches have been up to now used to elucidate the molecular mechanisms involved in plaque formation as
well as to identify markers of pathology severity for early diagnosis or target of therapy. The aim of this study was
to characterize the plaque secretome. The advantage of this approach is that secretome mimics the in vivo
condition and implies a reduced complexity compared to the whole tissue proteomics allowing the detection of
under-represented potential biomarkers.
Methods: Secretomes from carotid endarterectomy specimens of 14 patients were analyzed by a liquid
chromatography approach coupled with label free mass spectrometry. Differential expression of proteins released
from plaques and from their downstream distal side segments were evaluated in each specimen. Results were
validated by Western blot analysis and ELISA assays. Histology and immunohistochemistry were performed to
characterize plaques and to localise the molecular factors highlighted by proteomics.
Results: A total of 463 proteins were identified and 31 proteins resulted differentially secreted from plaques and
corresponding downstream segments. A clear-cut distinction in the distribution of cellular- and extracellular-derived
proteins, evidently related to the higher cellularity of distal side segments, was observed along the longitudinal axis
of carotid endarterectomy samples. The expressions of thrombospondin-1, vitamin D binding protein, and vinculin,
as examples of extracellular and intracellular proteins, were immunohistologically compared between adjacent
segments and validated by antibody assays. ELISA assays of plasma samples from 34 patients and 10 healthy
volunteers confirmed a significantly higher concentration of thrombospondin-1 and vitamin D binding protein in
atherosclerotic subjects.
Conclusions: Taking advantage of the optimized workflow, a detailed protein profile related to carotid plaque
secretome has been produced which may assist and improve biomarker discovery of molecular factors in blood.
Distinctive signatures of proteins secreted by adjacent segments of carotid plaques were evidenced and they may
help discriminating markers of plaque complication from those of plaque growth.
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Atherosclerosis is a chronic immune-inflammatory disease
of the wall of medium- and large-sized arteries and it is
the main cause of morbidity and mortality in Western
countries due to acute cardiovascular events secondary to
partial or total thrombotic obstruction of vessel lumen
[1,2]. Rupture of carotid atherosclerotic plaques leads to
atherothrombosis that accounts for approximately 20% of
all strokes, a leading cause of disability, and the third most
common cause of death [3].
Recently, a great interest has been focused on the
identification of tissue markers of atherosclerosis, at
genomics, transcriptomics [4] or proteomics levels. The
majority of proteomics studies were performed on
plaque extracts analyzed by two-dimensional electro-
phoresis followed by MALDI TOF mass spectrometry
[5,6], but, with this approach, mainly constitutive pro-
teins are identified and potential, usually low-expressed
biomarkers may not be detected. To overcome these
limitations, Olson et al. [7] applied two-dimensional dif-
ferential gel electrophoresis (2D-DIGE) in combination
with tandem mass spectrometry (MS/MS) to compare
protein distribution in an intra-individual study of se-
verely atherosclerotic segments of internal carotid artery
compared to partially preserved segments. In this way,
they identified 19 proteins with a differential distribution
along the artery. Another interesting approach was
exploited by Martinet et al. [8] who screened human ca-
rotid endarterectomy (CEA) specimens using 823 mono-
clonal antibodies with Western array technology and
were able to identify 7 differentially expressed proteins.
The potential use of tissue proteomics as a tool for
clinically useful biomarker discovery has been recently
prospected by de Kleijn et al. [9] who found that
osteopontin expression in carotid plaques and in blood
is predictive for atherothrombotic events but it does not
correlate with vulnerability features.
An alternative proteomics approach consists of the
analysis of proteins secreted by explanted arteries and
was first suggested by Duran et al. [10]. The great advan-
tage of tissue secretome studies is that secretome
mimics the in vivo condition and implies a reduced
complexity compared to serum/plasma or entire tissue
proteomics as well as a much narrower protein dynamic
range, thus allowing the detection of under-represented
potential biomarkers.
In fact, in biomarker discovery, plasma represents the
sample of choice since it shows traces of all biological
events and, moreover, it can be easily and non-invasively
collected. On the contrary, in proteomics studies, plasma
proteome is hampered by major limits such as the high
dynamic range of plasma proteins and a great biological
variability. For all these reasons, the analysis of proteins
that are secreted by tissues into circulation has attainedinterest for discovery of novel biomarkers and it
represents a way to gain knowledge of biological mech-
anisms [10,11].
An optimal culture set-up of arterial secretome in
order to reduce plasma contamination and detect low
abundance proteins is a recent achievement [12]. Also
recently, secretomes from thromboendartectomy speci-
mens were exploited to select nine secretome-specific
antibodies that allowed the immuno-purification and
successive identification of 22 proteins. Among them,
junction plakoglobin has been suggested as a potential
biomarker of atherosclerosis [13].
A main issue in molecular studies of vascular path-
ology is the cellular and extracellular heterogeneity of
the plaque and of the adjacent wall where multiple com-
ponents (calcium, lipids, collagens and others) and cell
types (vascular smooth muscle cells (VSMCs), endothe-
lial cells (EC), macrophages and other inflammatory
cells) are present, all contributing to plaque progression
and/or complication.
Several previous and recent papers have highlighted a
close link between the longitudinal distribution of mech-
anical forces (flow shear stress and plaque wall stress)
and corresponding morphological features (cell distribu-
tion and type) along plaque and its distal side [14-18]. In
particular, the low flow shear stress in downstream side
is associated to atherosclerosis progression with in-
creased VSMCs and macrophages, whereas the high
plaque wall stress in the upstream area is associated to
cap rupture of vulnerable lesions and increased expres-
sion of proteolysis and apoptosis markers [14]. These re-
ports support the opinion that carotid plaque and its
corresponding adjacent distal side may retain distinctive
protein signatures: therefore, differential expression of
proteins released by plaque-containing upstream seg-
ment (P) and by its downstream distal side (DS) segment
has been evaluated in each CEA specimen.
Aims of the study were: (a) to characterize the overall
atherosclerotic carotid secretion with an untargeted ap-
proach able to reconstruct a complete protein map; (b)
to evaluate the differences in secretomes from central
plaque and corresponding distal side segments, as puta-
tive areas of plaque complication and stable growth re-
spectively; (c) to conduct a secretome-assisted plasma
analysis of some differentially expressed proteins to be
exploited as markers of disease for non-invasive risk
assessment.
Secretomes were analyzed by a liquid chromatography
approach coupled with mass spectrometry (LC-MS/MS).
Label-free MS/MS based quantification was performed
and validated by Western blot analysis and ELISA assay.
Histology and immunohistochemistry were performed to
characterise CEA specimens and to localize the molecu-
lar factors highlighted by proteomics. ELISA assays of
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performed in plasma samples of 34 CEA candidates and
10 healthy controls.Methods
Ethics statement
Clinical data were derived from medical records, follow-
ing data security guidelines and declaration of Helsinki.
All subjects gave written informed consent to participate
to the study in accordance with the Ethics Committee
requirements. The ethical approval for this study was
granted by Ethics Commission (Clinical Trials Ethics
Commission) of Pisa University Hospital.Patient clinical characterization
Human internal carotid artery (ICA) specimens and pre
surgery plasma samples from 10 males and 4 females
undergoing CEA for symptomatic or asymptomatic sten-
osis ≥70% were obtained from the Vascular Surgery Unit
of Pisa University Hospital and immediately processed at
the Institute of Clinical Physiology. Additional 20 plasma
samples of CEA candidates and 10 plasma samples of
healthy volunteers were collected at the Vascular Surgery
Unit of Pisa University Hospital and at the Institute of
Clinical Physiology respectively.
Patient characteristics and database information on
smoking habit, hypercholesterolemia and diabetes are
summarized in Table 1.Table 1 Clinical characteristics of population
Feature Value (±SD)
CEA patients fo
secretome (N=1
Gender Females (n) 4
Males (n) 10
Age (years±SD) 72±9
Symptomatic (n) 6
Type of event Stroke (n) 2
TIA (n) 4
Asymptomatic (n) 8
Stenosis of ICA (%±SD) 80±9*
Diabetes (n) 6
Hypertension (n) 10
Smoking (n) 4
Statin treatment (n) 10
AntiaggregantTherapy (n) 14
Hypercholesterolemia (n) 4
Categorical values are given as number of patients (n).
Continuous variables are given as mean±SD.
TIA: Transient Ischemic Attack. ICA: Internal Carotid Artery.
*Stenosis was measured by carotid EchoColor Doppler.Symptomatic patients were classified as CEA candi-
dates who presented with TIA or stroke within 6 months
before surgery.
No differences between symptomatic and asymptom-
atic patients were found for any of the reported parame-
ters. Smokers were classified as individuals who smoked
at least three cigarettes per day at the time of analysis,
past smokers had quit smoking for at least 6 months,
and no-smokers were individuals who had never
smoked. Smoker patients were the combined group of
the past- and the current-smokers.
Stenosis on ICA was ≥ 70% at carotid Echocolor
Doppler in all patients, whose CEA specimen secretomes
were analysed (mean 80±9%), without significant
differences between asymptomatic and symptomatic
(79±8 vs 82±10 %).
Tissue processing and secretome preparation
The arterial tissue was cultured according to de la
Cuesta et al. [12] with modifications. CEA specimens
(n=14) from surgery were transported in PBS on ice to
the laboratory. Each specimen was crosscut under
macroscopic examination to separate P from DS seg-
ment. After repeated washing in PBS to remove blood
traces, samples were incubated in 6-well plates in 2 ml
of Eagle's Minimal Essential Medium (Sigma-Aldrich)
supplemented with penicillin and streptomycin, without
FBS and phenol red at 37°C in a humidified atmosphere
of 5% CO2. After 24 h the culture medium was
harvested, centrifuged at 300× g for 10 min and storedValue (±SD) Value (±SD)
r
4)
CEA patients for plasma
validation (N=34)
Healthy volunteers
(N=10)
10 4
24 6
74±7 70±5
11 -
3 -
8 -
23 -
79±8* -
9 -
27 1
13 1
21 -
32 -
18 2
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centrifugal devices Amicon Ultra-3 (Millipore) following
the manufacturer's recommendations. Protein concen-
tration was determined by bicinchoninic acid (Pierce).
Histology and immunohistochemical characterization
After 5 to 7 day fixation in 5% buffered formalin, P and
DS samples were incubated in decalcifying solution (Bio-
optica 05-M0300 ), washed and dehydrated in ascending
alcohols series and embedded in paraffin: transverse
5 μm thick consecutive sections were cut from each
paraffin block by a rotary microtome (Microm HM
300, Bio-optica). Haematoxylin and Eosin (H&E) and
Masson’s trichrome stains were used for histologic ana-
lysis. For immunohistochemistry, sections were placed
on positively charged slides, de-paraffinized, rehydrated
and washed in distilled water; after incubation in H2O2
at room temperature, antigen retrieval was accomplished
(citrate buffer pH6 in microwave for 10 min at 500W)
and then sections incubated with diluted normal
blocking serum. Primary antibodies anti-αSMA (alpha
smooth muscle actin, clone 1A4 ADB, Serotec) as a
SMC phenotype marker, anti-CD68 (mouse, clone PG-
M1, Thermo Scientific, diluted 1:150) as a macrophage
phenotype marker, anti-vinculin (goat polyclonal antibody
diluted 1:100, Santa Cruz Biotechnology, Inc.) and anti-
thrombospondin-1 (mouse polyclonal antibody diluted
1:100, Santa Cruz Biotechnology, Inc.) were applied over-
night to the slides in a 4°C humid chamber.
Following 30 min biotinylated secondary antibody and 30
min Vectastain Elite ABC reagent incubation in peroxidase
substrate solution (DAB), slides were counterstained
with Mayer’s haematoxylin for 1 min. and mounted
(Neo-Entellan Merk). Antibody binding to cells and/or to
extracellular components is visible as brown or dark brown
stain (DAB), negative cells are stained blue (haematoxylin
counterstain).
The same steps had been previously applied to a pool
of CEA specimens (from symptomatic and asymptom-
atic patients) which were processed en bloc and longitu-
dinally, instead of transversely, sectioned by microtome:
microscopic examination of the obtained serial sections
helped to guide and standardise the splitting of fresh
CEA samples, subsequently collected for secretome, into
P and DS segments.
Thrombospondin-1 and vinculin double immunostain-
ing was performed using Vectastain Elite ABC reagent
incubation in phosphatase (AP) substrate solution and
Permared-AP stain for thrombospondin-1 and DAKO
LSAB system HRP and subsequent peroxidase substrate
solution (DAB) incubation for vinculin.
All sections from each carotid segment were examined
under a light microscope (Olympus BX43) at 4× to 40×
original magnification and digitized by a video system(Olympus D70 camera) interfaced to Olympus Cell Sens
Dimension software for image acquisition and morpho-
metric analysis. Quantitative analysis of antibody stain-
ing within the lesional area of each sample was carried
out on several microscopic fields of consecutive sections,
digitized at the same light source settings, by double
observer colour thresholding: reproducibility and statis-
tical significance of results (expressed as% positive, dark
brown pixels of the entire plaque area) as well as
localization of different antibodies on the same region of
adjacent sections was thus accomplished.
Carotid plaques were classified according to Stary’s
stages for atherosclerosis, American Heart Association
Committee on Vascular Lesions [19,20].
Reduction, alkylation and digestion
100 μL of 40 mM ammonium hydrogen carbonate
(pH=8) were added to 100 μL of secretome (1 μg/μL
concentration). Reduction was obtained by adding 1 μL
of 1 M dithiothreitol to each sample, with an incubation
of 20 min at 80°C. For alkylation, 20 μL of 100 mM
iodoacetamide were added to the samples and incubated
for 30 min at 37°C. Digestion was performed incubating
overnight with 8 μL of trypsin solution (0.25 mg/mL)
at 37°C.
LC-MS/MS analysis
Chromatographic separation of peptides was performed
using an Ultimate 3000 nano-HPLC system (LC Pack-
ings, DIONEX, USA). 100 μL of filtrate were added to a
solution composed by 2% ACN and 0.1% formic acid up
to 200 μL of final volume. The loading pump pre-
concentrated the sample in a pre-column cartridge
(PepMap-100 C18 5 mm 100 A, 30 mm id × 5 mm).
Chromatographic separation of peptides was performed
using a C18 PepMap-100 column (15 cm × 75 mm id,
LC Packings DIONEX) equilibrated at 45°C with a solv-
ent A (water/acetonitrile 98/2 vol/vol, 0.1% formic acid)
at a flow rate of 300 nL min-1. Runs were performed
under 60 min linear gradient from 10 to 45% of solvent
B (water/acetonitrile 2/98 vol/vol, 0.1% formic acid)
followed by 10 min of a purge step at 95% of B before a
20 min re-equilibration step to the starting conditions.
The column was directly coupled to TripleTOF™ 5600
System (AB SCIEX, Toronto, Canada), equipped with a
DuoSpray™ ion source (AB SCIEX, Toronto, Canada).
Peptides eluted from chromatography were directly
processed using TripleTOF™ 5600 mass spectrometer
(AB SCIEX, Toronto, Canada). The mass spectrometer
was controlled by Analyst® 1.6.1 software (AB SCIEX,
Toronto, Canada). For positive ionization, ion source pa-
rameters were the following: the spray voltage was 3 kV,
source temperature 150°C with curtain gas set at 25,
GS1 10 and GS2 0 psi nitrogen flow. For information
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acquired in 250 ms and 25 product ion scans were col-
lected if exceeding a threshold of 125 counts per second
(counts/s). Total cycle time was fixed to either 1.25 s.
Four time bins were summed for each scan at a pulser
frequency value of 11 kHz through monitoring of the 40
GHz multichannel TDC detector with four-anode/chan-
nel detection. Dynamic exclusion was set for 1/2 of peak
width (∼8 s), and then the precursor was refreshed off
the exclusion list.
Protein identification and label-free comparative analysis
MS/MS data were processed with ProteinPilot™ Software
(AB SCIEX, Toronto, Canada), using the Paragon™ and
Pro Group™ Algorithms and SwissProt 2011 as protein
database for Homo Sapiens. The false discovery rate
(FDR) analysis was done using the integrated tools in
ProteinPilot software and a confidence level of 95% was
set.
The statistical comparative analysis was performed
using MarkerView™ Software 1.2.1 (AB SCIEX). The ion
chromatograms of high confidence peptides identified by
ProteinPilot were extracted using PeakView™ Software
and then MS peak areas and identifications were
imported into MarkerView™ Software. Normalization of
the total plaque size was obtained using a global
normalization of profiles (total protein content) using
Marker View 1.2 software.
Principal Component Analysis (PCA) was performed
in order to evidence groupings among the data set. All
profile areas were normalized. The two groups (P and
DS) were compared with t-test using a threshold of 95%
(P value=0.05) and fold change > 2.
Western blot analysis
Secretomes were run on a 10% SDS-PAGE, separated
proteins transferred onto a nitrocellulose membrane
(Amersham) using a wet transfer system (Biorad). Mem-
branes were blocked with 3% BSA in TBST for 1 h at
room temperature. Primary and secondary antibodies
were diluted in 3% BSA in TBST. All primary antibodies
were incubated overnight at 4°C. HRP-conjugated
secondary antibodies were incubated for 1 h at
room temperature. The following antibodies were used:
anti-vinculin goat polyclonal antibody (1:500) (catalog
number sc-7648, Santa Cruz Biotechnology, Inc), anti-
thrombospondin-1 mouse monoclonal antibody (1:200)
(catalog number sc-73158, Santa Cruz Biotechnology,
Inc), and anti-α tubulin mouse polyclonal antibody
(1:5000) (catalog number T 6074, Sigma). Chemi-
luminescence was detected with ECL™ detection kit
(Amersham Biosciences, Uppsala, Sweden).
Densitometric quantification of photographic films was
performed using Quantity One 1-D Analysis Software(Bio-Rad). Photographic films were scanned and the
pixel intensities of bands was measured subtracting the
pixel intensity of the background and all the signals
were recorded as Optical Density (O.D.). All the O.D.
were reported in graphs and the comparative analyses
of the different levels of expression of vinculin and
thrombospondin-1 between P and DS samples was done
integrating the resulting area under curve by using Origin
7.0 (Originlab).
ELISA assays
Dosage by double-antibody sandwich enzyme-linked im-
munosorbent assay (ELISA) was performed on vitamin
D binding protein and thrombospondin-1.
ELISA kits were used and reagents were prepared fol-
lowing the manufacturer's manual. Briefly, for vitamin D
binding protein (Uscn Life Science Inc, Wuhan, China)
the calibration curve ranged between 10 and 0.156 ng/
mL (considering a dilution for plasma samples of
200000-fold) and the calibrator diluent was used as the
zero standard. All standards and samples were assayed
in duplicates.
For thrombospondin-1 assay (Bio Medical Assay,
Beijing, China) the calibration curve ranged between 20
and 0.312 ng/μL. Plasma samples were diluted 100 fold.
The ELISA assay for Vitamin D binding protein
(Quantikine® ELISA Human Immunoassay- USA &
Canada R&D Systems, Inc.) was performed also on
secretome samples without dilution. The calibration
curve ranged between 1000 ng/ml and 15.5 ng/ml. The ab-
sorbance was read at 450 nm with a Fluorstar (Omega)
microplate reader (Molecular Devices, Sunnyvale, CA).
Statistical analysis
Principal component analysis (PCA) was conducted on
mass spectrometric data of samples using Marker View
1.2 software.
Student’s t Test was used as statistical parameter between
the means of continuous variables to determine significant
differences between categories of mass spectrometric data.
P value < 0.05 were considered significant to validate differ-
ences between categories and fold change > 2.
Statistical analyses of other data were conducted using
Origin 7.0 software. Data are expressed as the mean ±
SD. Differences between the means of the 2 continuous
variables were evaluated by the Student’s t Test and re-
sults accepted when t Test>95% and P value<0.05.
Paired t test was used for quantitative immunohisto-
chemistry and ELISA assay.
Ingenuity pathway analysis (IPA)
IPA (http://www.ingenuity.com/products/pathways_analysis.
html) was performed on a restricted and selected number
of identified proteins (n=56) from the secretomes of CEA
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of 34 extracellular matrix proteins, 9 plasma membrane
proteins and 13 intracellular proteins. This subset of pro-
teins was related to five function/disease pathways: migra-
tion of cells (n=39), proliferation of smooth muscle cells
(n=9), vascular disease (n=11), atherosclerotic lesion (n=8)
and angiogenesis (n=22). Colored points were used to
evidence differentially released proteins between P and DS.
Results
Morphological characterization
Microscopic examination of longitudinal sections of un-
divided CEA specimens evidences a plaque core
containing area (P) comprised of typical components
(lipid-rich necrotic core, fibrous cap, cholesterol clefts,
large calcium deposits, intraplaque haemorrage/ fresh
thrombi) and the distal side segment (DS) with
fibromuscular tissue, small extracellular lipid and cal-
cium deposits. Fresh CEA specimens for secretome were
subsequently divided to separate central plaque P from
its distal side DS, as depicted in Figure 1.
Sections from all CEA specimens, each cut in two (P and
DS) were examined and classified for the presence of histo-
logic hallmarks of atherosclerosis, including lipid-rich
necrotic core, cholesterol clefts, fibrosis, calcium, thin
fibrous caps, macrophage infiltrate, neovessels, intraplaqueFigure 1 Longitudinal section of an undivided CEA specimen at arter
segments separation. Prevalent complicated plaque features of P (lipid-ne
changes of its downstream side DS (prevalent VSMCs and collagen compo
trichrome and α-SMA immunostaining (from top to bottom). Original maghaemorrhage/thrombi. The DS segments, although free of
grossly evident changes, showed small lesions at histologic
examination, with atherosclerotic features similar to those
classified as Stary’s types III and IV. Proximal P segments,
on the other hand, showed grossly evident fibrolipidic and/
or fibrocalcific, mostly complicated plaques classified as
types V and VI (Table 2) [19,20].
Masson’s trichrome stain, αSMA and CD68 immuno-
staining representative of P and DS segments are shown
in Figure 2; the quantitative analyses for αSMA and
CD68 are also reported, demonstrating a significantly
higher content of VSMCs and CD68 positive macro-
phages in the distal side as compared to central plaque
region (Figure 2).
Secretome analysis of endarterectomy specimens
P and DS segments from the 14 enrolled patients were
incubated for 24 h in serum free medium, secretomes
were collected, protein digested and peptides fraction-
ated by reverse phase chromatography and analyzed by
5600 TripleTOF mass spectrometer.
Using this LC-MS/MS approach, 463 proteins were
identified with a Protein Score (Confidence) > 95% and
using local false discovery rate analysis >1% as stringent
criterion to avoid false positives (Additional file 1: Table
S4 and Additional file 2: Table S5). The entire list ofy center line level showing the cutting line for P and DS
crotic core, calcium deposits, fibrosis and haemorrage) and milder
nent, small lipid and calcium deposits) are evidenced by Masson’s
nification 2×, insets 10×.
Table 2 Histologic characterization of P and DS samples
P (% specimens) DS (% specimens)
TFCA(1) 33 0
Ca(2) 65 10
NC-Chol(3) 75 20
He(4) 35 0
(1) TFCA= thin fibrous cap, (2) Ca = calcification, (3) NC-Chol=necrotic core
cholesterol clefts.
(4) He = intraplaque hemorrhage/thrombus.
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in the context of the published literature and firstly
grouped as extracellular and intracellular proteins. Using
Uniprot database (www.uniprot.com), extracellular proteins
were further subdivided in ECM proteins and ECM-
associated proteins. The intracellular ones were groupedFigure 2 Left: P and DS sections stained with (a) Masson’s trichrome
magnification 2×, insets 10×). P is a type VI plaque with a necrotic core,
of collagen and αSM-actin positive cells; minor intraplaque CD68 positive s
visible on the outer border of the specimen (opposite to the lumen) due t
much thinner lesion (equivalent to Stary type III) with extensive α -SMA an
Average values and SD of lesional area (mm2), intralesional α-SMA and CD6
specimens’ sections: a smaller lesional area and a markedly higher positivity
(*p<0.05, **p<0.02 paired t-test).considering their localization in cytosol, membrane, organ-
elle, cytoskeleton and others (Figure 3A).
The secretion potential of these identified proteins was
computed by submitting them to SecretomeP server that
predicts protein secretion route on the basis of the
presence of the signal peptide, responsible for endoplas-
mic reticulum addressing. The non-classical secretion
through multi vesicular bodies was also determined by
SecretomeP using specific databanks [21] (Figure 3B).Comparative analysis between plaque and its distal
counterpart secretomes
In order to evaluate differentially released proteins be-
tween P and DS specimens, MarkerView 1.2 software
was used and 31 proteins were found differentiallystain, (b) α-SMA and (c) CD68 immunostain (original
calcifications, intraplaque thrombus and a thin fibrous cap composed
taining is present and α-SMA -actin positive contractile VSMCs are also
o surgical cleavage of plaque from the intact tunica media. In DS, a
d CD68 cellular positivity is present. Right: From top to bottom.
8 stain positivity (% of lesional area) of P and DS segments of all
of both cellular markers in the distal side of the plaque is evident
Figure 3 Pie charts of the total identified proteins from P and DS. A) Identified proteins are divided on the basis of their localization in
intracellular or extracellular space based on Gene Ontology. B) Identified proteins are evaluated with SecretomeP software to compute their
secretion potential. They were divided in 1) classically secreted 2) not-classically secreted and 3) not-predicted.
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egories: cellular (n=17) and extracellular proteins (n=14)
(Table 3). The putative role of each factor in atheroscler-
osis and cardiovascular disease was reported in the table
as suggested by the literature, in order to underline
a possible correlation of their dis-regulation to the
pathology.
Nine out of the 14 extracellular proteins were found
over-expressed in P secretome, whilst cellular proteins
were found over-expressed in DS secretome, with the
exception of smoothelin, which is a recognized marker
of VSMC contractile phenotype [23]. Of these proteins
eighteen have been already reported in serum/plasma
and listed in Human Protein Reference database (www.
hprd.org). Origin 7.0 was used to represent the modula-
tion of the differentially released proteins and the most
interesting are reported as representatives of the results
(Figure 4).
Validation by Western Blot and ELISA assay
Western Blot analysis and also ELISA assay were applied
to secretomes in order to validate the differential release
observed by mass spectrometric analysis. Vinculin and
thrombospondin-1 were selected for Western blot valid-
ation (Figure 5A), while vitamin D binding protein was
selected for ELISA assay (Figure 5B).
Immunohistochemistry quantification
Double immunostaining of anti-vinculin and anti-
thrombospondin-1 antibodies on P and DS sections of a
CEA specimen is shown in Figure 6. Anti-vinculin antibody
selectively stains lesional cells whereas thrombospondin-1stain is confined to the plaque lipid-necrotic core and
surrounding fibrous cap.
Quantitative results derived from single immunostain-
ing of both markers on sections of all CEA specimens
confirm the significantly higher (6.4±5.0 vs 3.4±3.0
P<0.02) vinculin positivity and the much lower (0.8±0.8
vs 7.3±6.0 P<0.02) thrombospondin-1 positivity in the
lesion area of DS as compared to corresponding P
segments.
ELISA assay of plasma samples
Dosage by double-antibody sandwich ELISA assays of
thrombospondin-1 and vitamin D binding protein were
performed in plasma samples of 34 CEA patients and 10
age-matched healthy controls. As reported in Table 1, 11
patients were symptomatic while 23 were asymptomatic.
Plasma levels of thrombospondin-1 and vitamin D bind-
ing protein were significantly higher in atherosclerotic
patients than in healthy subjects (thrombospondin-1:
71±20 vs 48±9 ng/mL P value= 0.02; Vitamin D binding
protein: 205±133 vs 76±8 ng/mL P value= 0.05), while
no significant differences were observed between symp-
tomatic and asymptomatic patients (thrombospondin-1:
67±14 vs 72±20 ng/mL P value=0.72; vitamin D binding
protein: 234±137 vs 192±122 ng/mL P value=0.69)
(Figure 7).
Discussion
Several proteomics approaches have been carried out on
in order to clarify the mechanisms of atherogenesis as
well as to search for plaque presence and severity. The
majority of these studies concern carotid atherosclerosis.
Table 3 Differentially released proteins by CEA specimens
Localization Protein name (1) Gene
name
Role in atherosclerosis (2) P/DS
(3)
P value
(4)
Plasma
(5)
Cellular Alpha-actinin 1 ACTN1 Focal adhesion ▼ 6.70E-04 ☑
Integrin-linked protein kinase ILK Focal adhesion ▼ 1.10E-04 ☑
Actin-related protein 2/3 ARPC3 Focal adhesion ▼ 1.20E-04 ☑
Filamin A FLNA Focal adhesion ▼ 1.35E-05 ☑
PDZ and LIM domain protein 1 PDLI1 Focal adhesion ▼ 1.34E-03 ☑
PDZ and LIM domain protein 7 PDLI7 Focal adhesion ▼ 5.70E-04 ☑
Vimentin VIM Focal adhesion ▼ 2.02E-03 ☑
Vinculin VCL Focal adhesion [12] ▼ 2.80E-04 ☑
Cysteine-rich protein 2 CRIP2 SMC differentiation [22] ▼ 1.10E-04
Calponin 1 CNN1 SMC differentiation ▼ 1.90E-04
Calponin 2 CNN2 SMC differentiation ▼ 2.57E-03 ☑
Calponin 3 CNN3 SMC differentiation ▼ 1.10E-04
Transgelin TAGL SMC differentiation ▼ 3.00E-03
Tropomyosin-1 alpha TPM1 SMC differentiation ▼ 2.63E-03 ☑
Tropomyosin beta TPM2 SMC differentiation ▼ 1.14E-03 ☑
Smoothelin SMOO SMC differentiation and plaque
stability [23]
▲ 3.40E-04 ☑
Vascular cell adhesion protein 1
(VCAM-1)
VCAM1 Monocyte recruitment ▼ 1.39E-02 ☑
Extracellular matrix
(ECM)
Collagen alpha 1 (III) COL3A1 Plaque stability ▲ 1.70E-04
Collagen alpha 1 (VI) COL6A1 Plaque stability ▲ 2.40E-04
Collagen alpha 1 (XIV) COL14A1 Atherogenesis ▲ 1.05E-03
Collagen alpha 1 (XVI) COL16A1 Atherogenesis ▲ 2.07E-03
Versican VCAN Atherogenesis [24] ▲ 1.45E-05
Lumican LUM Plaque rupture [24] ▲ 4.07E-02 ☑
Fibulin 2 FBLN2 Cell migration [25] ▲ 9.00E-03
Emilin 1 EMILIN1 Elastic lamellae integrity [26] ▲ 1.82E-03 ☑
Periostin POSTN Angiogenesis ▲ 2.07E-03
Thrombospondin-1 THBS1 Angiogenesis [27] ▲ 1.71E-02 ☑
Vitamin D binding protein GC Acute events [28,29] ▲ 1.93E-02 ☑
Apolipoprotein A-II APOA2 Lipid transport ▲ 1.28E-03 ☑
Apolipoprotein D APOD Lipid transport ▲ 3.11E-05 ☑
Aggrecan ACAN Lipoprotein retention ▲ 1.51E-05
(1) Protein name is reported according with SwissProt 2011 database. (2) Role in atherosclerosis is referred to data reported on the recent literature (3) ▼: down
released in P compared with DS; ▲: up released in P vs DS. (4) P values were generated using Marker View software. (5) Their presence in plasma was showed
according to Human Protein Reference database (www.hprd.org).
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low sensitive and low-throughput methods, identified
only a small number of proteins, restricting considerably
the detection of novel low abundant biomarkers.
Lepedda et al. [6] identified 9 differentially expressed
proteins in unstable compared to stable plaques while,
only one year later, Olson et al. [7] suggested 19 proteins
with a differential distribution in stable compared to
more complicated carotid segments of the same patients.
To increase sensitivity in the search of new biomarkers,high-throughput western blot analyses and microarray
technology were performed allowing the finding of 7 differ-
entially expressed proteins [8] and 11 proteins distributed
between stable and unstable plaques [30]. A tissue proteo-
mics study has recently identified and demonstrated that
osteopontin tissue expression in carotid plaques and its
plasma levels are predictive of adverse cardiovascular
events in all atherosclerotic vascular districts [9].
One of the first pioneering secretome studies, using two-
dimensional gel electrophoresis, allowed the identification
Figure 4 Differential protein expression obtained by mass spectrometric analysis of P and DS. Four of the 31 proteins reported in table 3
are chosen and comparative expression analysis is presented as Box plots. Box plots show median value, standard deviation (SD), 50%, minimum
and maximum intensity values and were exported from Marker View software.
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segments [12], but only recently, in order to avoid high
abundant plasma protein contamination, Cooksley-
Decasper and colleagues [13] studied the secretomes from
carotid plaques combining antibody phage display with
mass spectrometry. This last approach couples sensitivity
and accuracy providing a direct detection of secreted pro-
teins in blood. The method is quite complex respect to the
full-screen untargeted approach chosen in our study and
the number of identified proteins is rather limited, thus
restricting the “discovery potential” of that approach.
In our study the secretome of human carotid plaques
was tackled with a high performance, very sensitive, gel-
and label-free LC-MS/MS workflow. The unbiased ap-
proach, able to give a high sensitive full screen overview
of secreted proteins from human carotid artery, is
presented here for the first time. This method allowed
the identification of 463 proteins thus producing a wide
shot on proteins released by atherosclerotic arteries. Themajority of the identified proteins (70%) are predicted as
secretory proteins by SecretomeP software. 40% of these,
due to the presence of the characteristic signal peptide,
are likely to follow the classical exocytosis pathway
across the Golgi apparatus. The other proteins are non-
classically secreted through microvesicles and multi vesicu-
lar bodies-derived exosomes, as evidenced by the inclusion
in ExoCarta databank (http://www.exocarta.org).
In our procedure, CEA specimens were cut in P and
downstream DS segments in order to compare the
secretomes of the upstream area of maximum stenosis to
that of partially preserved downstream area, subjected to
distinct flow shear stress and wall strain regimen. P seg-
ments were classified as Stary’s types V and VI [19,20],
while DS segments displayed less severe wall changes.
We considered this approach useful to differentiate
specific molecular factors of the central plaque area,
where complication features are present, from those of
its distal side.
Figure 5 Left: Western blot analysis of P and DS secretomes. Densitometric quantification of vinculin and thrombospondin-1 using Quantity
One 1D analysis software. Representative images: 10 μg of proteins were separated on SDS-PAGE and blotted on nitrocellulose membrane.
Immunoblots were probed with antibodies against vinculin and thrombospondin-1. Right: ELISA assay for vitamin D binding protein expression in
secretome samples (P and DS).
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studies have been focused on plaque classification and
are based on cross-sectional observations, without taking
into account the longitudinal heterogeneity and asym-
metry within the atherosclerotic CEA specimens, it has
been recently recognized that the upstream side is asso-
ciated with an increased incidence of severe lesions with
cap rupture, while the downstream side is associated
with higher VSMC content and it could thus be more
representative of cellular growth [14,17,18].
According to this line of reasoning, we found that pro-
teins involved in ECM organization are more repre-
sented in P secretome while proteins concerning VSMC
phenotype switch, cell contraction and migration, as well
as focal adhesion pathways are more abundantly released
by DS segments. These observations confirm and
strengthen the role of VSMC activation in the early
stages of plaque development [31,32] and, conversely,
the role of ECM substrates and matrix remodeling in
mature plaques [24,26].
Pathway analysis was chosen to relate identified
proteins to their cell function and/or pathological role
in vascular diseases. As evidenced by IPA clusters
(Figure 8) almost all proteins reported as involved inatherosclerotic lesion and vascular disease are also re-
lated to migration and proliferation of cells, reinforcing
the primary role of VSMCs in plaque progression.
Secretome expression of vinculin and thrombospondin-1
have been validated by western blot analyses: the first one
being an intracellular protein, involved in cell migration,
the latter one as representative of ECM-related proteins
and reported to control atherosclerotic plaque maturation
[12,27]. Single and double immunostaining confirmed west-
ern blot results of differential protein distribution along
CEA specimens, at the same time excluding significant tis-
sue colocalization. A sandwich ELISA assay was also used
to confirm the differential secretion of vitamin D binding
protein, an extracellular protein reported as marker of acute
events [28,29]. Both western blots and ELISA tests validated
the mass data on secretomes.
Amongst the 463 identified proteins, 31 resulted
differentially secreted by P and DS samples. Half of
them were extracellular factors, most of which already
reported in plasma, according to Human Protein Refer-
ence Database, suggesting that, once released from tis-
sue, they could be found in peripheral blood. For this
reason, vitamin D binding protein and thrombospondin-1
were measured in plasma samples of CEA candidates and
Figure 6 Top: Double immunostaining of thrombospondin-1 (red) and vinculin (brown) in P (A) and DS (B) sections of a fibrocalcific
type Vb plaque. Low magnification (2×, left) and high magnification (10× to 40×) microscopic fields (insets) are shown. Neither cellular nor
extracellular co-distribution of the two antibodies is present. A selective cellular binding of vinculin both on P an DS sections is evident, while
thrombospondin-1 is almost exclusively located in the fibrocalcific core of P. Bottom: Average values and SD of thrombospondin-1 and vinculin
positivity (single immunostaining) in lesional area of all CEA specimens showing a markedly greater stain in P as compared toDS for
thrombospondin-1 and an opposite pattern for vinculin. *p<0.02 paired t-test.
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subjects. No significant association with symptomatol-
ogy was evidenced. The correlation between secretome
modulation and plasma levels of these two proteins
confirms that tissue-secreted protein analysis can beFigure 7 ELISA assay for thrombospondin-1 and vitamin D binding p
as symptomatic and asymptomatic and 10 healthy controls.helpful to search for novel disease-specific biomarkers
in blood and improve non-invasive risk assessment.
The clinical impact of secretome approach to vascular
pathology and atherosclerosis arises from the potential
use of plaque-secreted molecules as useful predictors ofrotein expression in plasma samples of 34 CEA patients classified
Figure 8 Ingenuity Pathway Analysis (IPA) of a subset of 56 proteins identified in the secretome of CEA specimens. Pathways were
generated based on the information stored in IPA Knowledge base. Nodes correspond to the 56 proteins and are reported with their Gene
Codes. Colors correspond to differentially released proteins between P and DS reported in Table 3. Red: up-released by P. Green: down-released
by P. Extracellular space, cytoplasm and plasma membrane proteins are shown based on IPA classification.
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secretome strategy can be able to differentiate progressing
from stable plaques as well as discriminating rupture-prone
from non-vulnerable plaques, leading to a proper selection
and optimal management of high risk patients [10].
This potentiality is challenged by clinical and bio-
logical limitations: (a) atherothrombosis accounts for no
more than 20% of strokes; (b) complicated ruptured
plaques can be asymptomatic, limiting markers specifi-
city; (c) site-specificity of arterial VSMCs and extent of
plaque vascularization can influence type and quantity
of proteins released in the blood.
Despite these restrictions, secretome analysis seems a
most valuable tool to disclose the molecular basis of
atherosclerosis as well as of several other diseases [33],
due to the unique combination of tissue specificity of
biomarkers and clinical feasibility of their detection
in blood, aimed to improve patient diagnosis and
monitoring.
Results of an untargeted secretome analysis are presented
in this study: this unbiased strategy, as compared totargeted analysis, may complicate a prompt clinical output
but it is surely the most adequate approach to unravel novel
disease markers.
The relatively small number of CEA specimens ana-
lyzed represents a limit and the lack of sample stratifica-
tion is the most relevant consequence of this fact.
Despite that, our high sensitive method evidences a very
broad spectrum of proteins in carotid plaque secretome
and comparative analysis between P and its DS overrides
inter-patient variability.
Two ECM proteins released by P are found signifi-
cantly higher in plasma from atherosclerotic patients
without differences between symptomatic and asymp-
tomatic ones, supporting the mismatch between plaque-
related and event-related factors, in agreement with
other findings [9].
A further clinical relevance of the present study relies
on the evidence that a large number of CEA secreted
proteins are asymmetrically distributed along the athero-
sclerotic vessel, related to plaque complication features:
this implies that a broader cellular and extracellular
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be required to increase specificity and predictive potential-
ity. Future studies are needed to specify secretome-plasma
proteins profiling at different stages of carotid plaque
growth and complication and its relation to clinical events.
Conclusions
Thanks to an optimized workflow, a detailed, broad
spectrum profile of the human carotid plaque secreted pro-
teins has been obtained. A large number of CEA-secreted
proteins are evidenced which result asymmetrically distrib-
uted along the atherosclerotic vessel according to their cel-
lular or extracellular origin, suggesting that markers of
stable plaque growth and those of plaque complication
could be exploited as biomarkers of distinct and specific
stages of disease.
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